Home › Companies › CGEM

Cullinan Therapeutics

Market cap $602M 64.9M shares (10-Q, Nov 4, 2026) × $9.28 close Nov 17, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. Zipalertinib + chemotherapy EGFR NDAby year-end 2026Zipalertinib + chemotherapy EGFR NDA, by year-end 2026, notable
  2. CLN-049 Ph2 readout4Q 2026CLN-049 Ph2 readout, 4Q 2026, notable
  3. CLN-978 readoutDec 2026CLN-978 readout, Dec 2026, material
  4. Velinotamig trial startearly 2027Velinotamig trial start, early 2027, routine
  5. Zipalertinib EGFR FDA decisionFeb 27, 2027Zipalertinib EGFR FDA decision, Feb 27, 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (10 active programs)

Discontinued (7)

Capital (as filed)

Cash
$88.3M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$201M Sep 30, 2026
Long-term investments
$21.9M Sep 30, 2026
Operating cash flow
−$43.1M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$393M cash, runway 2029 per the update of Jul 28, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (14)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (14 calls)

Every verdict Biotech Distilled has published on Cullinan Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Speculative buy speculative Cullinan Therapeutics (CGEM): Scientific Deep Dive for CLN-978 and Pipeline Products Cash runway and Zipalertinib milestones mitigate downside enough to make the CLN-978 autoimmune lotto ticket worth the price of admission, provided position is sized assuming the autoimmune program could fail.
  2. Speculative buy speculative UPDATE: Cullinan Therapeutics (CGEM) - A 14% Haircut on Housekeeping Filings The 14% drop on housekeeping filings is a gift; the binary CLN-978 autoimmune data readout in Q2 2026 remains the only thing that matters, and the thesis is unchanged.
  3. Speculative buy speculative UPDATE: Cullinan Therapeutics (CGEM) - The PDUFA Lands, the ATM Opens Zipalertinib PDUFA acceptance modestly de-risks the valuation floor, but the $200M ATM facility is a yellow flag on dilution discipline; the Q2 CLN-978 binary remains the dominant variable.
  4. Speculative buy speculative UPDATE: Cullinan Therapeutics (CGEM) - The Catalyst Has a Date and a Stage CLN-978 catalyst compressed to June 6 EULAR poster, ATM stayed untouched in Q1, and cash discipline is holding; the binary safety readout remains the setup.
  5. Buy core UPDATE: Cullinan Therapeutics (CGEM) - The Abstract Drop Front-Runs EULAR The EULAR abstract shows tissue-level B-cell depletion, clinical activity in RA and SLE, and a 'favorable safety profile' with no ICANS signal, materially de-risking the binary and warranting an upgrade from Speculative BUY to BUY.
  6. Buy core UPDATE: Cullinan Therapeutics (CGEM) - The Full Poster Lands, the Stock Sells the News Full EULAR poster confirms DORIS remissions in SLE, tissue B-cell depletion, and zero ICANS across 29 patients; Grade 3 CRS at 45 µg defines the dosing ceiling but does not break the program; sell-the-news mechanics appear to be a misread.
  7. Buy core UPDATE: Cullinan Therapeutics (CGEM) - The Second Leg Lands CLN-978 multi-dose tolerability held in first repeat-dose patients including a rituximab-refractory remission, and velinotamig's first human data printed clean with two complete renal responses and zero CRS/ICANS, giving the platform a credible second engine.
  8. Buy core UPDATE: Cullinan Therapeutics (CGEM) - The AML Hammer Gets a Regulatory Runway FDA agreed a seamless, potentially registrational single-arm Phase 2 for CLN-049 in R/R AML starting Q3 2026, adding a third engine with a defined regulatory pathway, though the 45% stock run since June narrows entry asymmetry.
  9. Buy core UPDATE: Cullinan Therapeutics (CGEM) - The Safety Net Turns Into a Second Engine REZILIENT3 Phase 3 met primary PFS at a planned interim, upgrading zipalertinib from a safety net to a franchise asset and firming the valuation floor, though no effect size is yet disclosed and immunology remains the re-rating variable.
  10. Buy core UPDATE: Cullinan Therapeutics (CGEM) - The Hazard Ratio Finally Shows Up REZILIENT3 full data shows HR 0.50 (P=0.00015), median PFS 14.5 vs 8.5 months, and 1.4% Grade ≥3 diarrhea validating wild-type sparing; the floor is now a decisive randomized result, but immunology still owns the ceiling.
  11. Buy core UPDATE: Cullinan Therapeutics (CGEM) - The Q3 Print Slides to December CLN-978 multi-dose RA durability read slipped from Q3 to December with no scientific explanation; thesis intact but two soft timing signals add a calendar asterisk; ACR velinotamig poster on November 8 is the next real read.
  12. Buy core UPDATE: Cullinan Therapeutics (CGEM) - The Frontline Filing Jumps the Line Taiho started a rolling frontline zipalertinib NDA under RTOR, putting up to $100M of milestone money on a faster track and making a 2027 frontline decision plausible, further firming the floor ahead of the December CLN-978 binary.
  13. Buy core UPDATE: Cullinan Therapeutics (CGEM) - The AML Hammer Gets Lighter CLN-049 composite remission rate compressed to 21% at 12 µg/kg from the 31% headline, marking the AML asset down from third engine to lottery ticket, but the zipalertinib floor and CLN-978 immune-reset thesis are untouched; December CLN-978 package is now the sole re-rating variable.
  14. Buy core UPDATE: Cullinan Therapeutics (CGEM) - The Second Engine Holds at n=12 Velinotamig's June signal held at sixfold the patient count with no Grade ≥3 CRS, no ICANS, 8 of 9 SLEDAI responders and 4 of 7 complete renal responses, confirming the second immunology engine; December CLN-978 durability package remains the binary event.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (10 quotes from 5 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (45)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

9 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)